On 28th November OxTalks will move to the new Halo platform and will become 'Oxford Events' (full details are available on the Staff Gateway).
There will be an OxTalks freeze beginning on Friday 14th November. This means you will need to publish any of your known events to OxTalks by then as there will be no facility to publish or edit events in that fortnight. During the freeze, all events will be migrated to the new Oxford Events site. It will still be possible to view events on OxTalks during this time.
If you have any questions, please contact halo@digital.ox.ac.uk
Robert Hills is Professor of Translational Statistics at the Centre for Trials Research, Cardiff University, and Lead for Clinical Cancer Research Methodology.
His interests include novel trial designs to maximise data from patients in increasingly genetically delineated conditions, and meta-analyses of data from different trials, including a recent individual patient data meta-analysis of gemtuzumab ozogamicin (mylotarg) which has been used to support licensing applications in The United States and the EU.
Since 2006 he has worked in Cardiff as statistician for the NCRI Trials in Acute Myeloid Leukaemia, including introducing the multi-arm multi-stage Pick-A-Winner design for older patients not suitable for intensive chemotherapy, which has so far accumulated data on a dozen comparisons. The NCRI AML trials have also accumulated over 10,000 samples, which has allowed investigations of both prognostic and predictive markers. These results have enabled improved risk stratification and the identification of patients who are not well served by current therapy.
In his talk he will explore the story of Mylotarg, from the first randomised controlled trial (AML15) in 2002 through to the recent approval by the FDA last autumn, including the role of the IPD meta-analysis.
